fimasartan + rosuvastatin

Fimasartan + rosuvastatin is a fixed-dose combination drug consisting of two active pharmaceutical ingredients used primarily for the management of patients with both hypertension and hypercholesterolemia. Fimasartan is an angiotensin II receptor antagonist (ARB) that lowers blood pressure by blocking the type-1 angiotensin II receptor, thereby preventing vasoconstriction and reducing aldosterone secretion, which leads to increased natriuresis and reduced blood volume. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol synthesis in the liver, leading to decreased plasma LDL cholesterol and triglycerides while increasing HDL cholesterol. The combination targets two major cardiovascular risk factors—high blood pressure and high cholesterol—and is intended to improve patient adherence by simplifying therapy regimens[1][2][3][6]. Developers: Boryung Pharmaceutical

Brand names

Kanarb PlusKanarb Duo

Other names

fimasartan/rosuvastatinfimasartan and rosuvastatin combination